Search for a trial

Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients

The primary objective of this study is to evaluate the inhibition of PACAP-38 induced migraine-like attacks by AMG 334Secondary objectives:* To evaluate the inhibition of PACAP-38 induced headaches by AMG 334* To evaluate the safety, tolerability,…

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache

Primary:The primary objective is to assess the efficacy of LY2951742 300 mg every 30 days compared with placebo in reducing the frequency of weekly cluster headache attacks in patients with episodic cluster headache. The primary outcome measure will…

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine - The CONQUER Study

The primary objective is to test the hypothesis that galcanezumab is superior to placebo in the prevention of migraine in patients with treatment-resistant migraine.The key secondary objective are:- To compare galcanezumab with placebo with respect…

The feasibility, desirability and effects of physical activity coaching and feedback on the level of physical activity of patients with migraine - a pilot study

Primary objective is firstly to test the feasibility and the desirability of an intervention including coaching sessions and a pedometer both to improve the level of physical activity of patients with migraine, secondly to explore the difference in…

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,
Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens
(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the
Prevention of Chronic Cluster Headache

The primary objective of this study is to demonstrate the efficacy of fremanezumab in the prevention of CCH in adult patients:- The primary efficacy endpoint of this study is the mean change from baseline (run-in period) in the monthly average…

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache

Primary objective:The primary objective is to assess the efficacy of LY2951742 300 mg every 30 days compared with placebo in reducing the frequency of weekly cluster headache attacks in patients with chronic cluster headache. The primary outcome…

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study

Primary To test the hypothesis that at least 1 dose of LY2951742 (120 mg or 240 mg/month) is superior to placebo in the prevention of migraine headache in patients with chronic migraineKey Secondary Objectives If LY2951742 (120 or 240 mg/month) is…

Randomized, double-blind, sham-controlled trial to investigate combined occipital and supra-orbital neuromodulation in resistant migraine. The RECLAIM study.

To evaluate the safety and performance, including clinical benefit, of the PRIMUS System for the treatment of Resistant Migraine.